Evidence map›Paper›PMID 34676381›Full record

ArticlebioRxiv : the preprint server for biology2021

Apropos of Universal Epitope Discovery for COVID-19 Vaccines: A Framework for Targeted Phage Display-Based Delivery and Integration of New Evaluation Tools.

Christopher Markosian, Daniela I Staquicini, Prashant Dogra, Esteban Dodero-Rojas, Fenny H F Tang, Tracey L Smith, Vinícius G Contessoto, Steven K Libutti, Zhihui Wang, Vittorio Cristini and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Christopher MarkosianRutgers Cancer Institute of New Jersey, Newark, NJ 07101.
Daniela I StaquiciniRutgers Cancer Institute of New Jersey, Newark, NJ 07101.
Prashant DograMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030.
Esteban Dodero-RojasCenter for Theoretical Biological Physics, Rice University, Houston, TX 77005.
Fenny H F TangRutgers Cancer Institute of New Jersey, Newark, NJ 07101.
Tracey L SmithRutgers Cancer Institute of New Jersey, Newark, NJ 07101.
Vinícius G ContessotoCenter for Theoretical Biological Physics, Rice University, Houston, TX 77005.
Steven K LibuttiRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901.
Zhihui WangMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030.
Vittorio CristiniMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030.
Paul C WhitfordDepartment of Physics and Center for Theoretical Biological Physics, Northeastern University, Boston, MA 02115.
Stephen K BurleyRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901.
José N OnuchicCenter for Theoretical Biological Physics, Rice University, Houston, TX 77005.
Renata PasqualiniRutgers Cancer Institute of New Jersey, Newark, NJ 07101.
Wadih ArapRutgers Cancer Institute of New Jersey, Newark, NJ 07101.

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
PDB MANAGEMENT BY THE RESEARCH COLLABORATORY FOR STRUCTURAL BIOINFORMATICSR01GM133198 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI BURLEY, STEPHEN K · 2019 to 2023
$19.3M
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate CancerR01CA226537 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI ARAP, WADIH, BRINKER, C JEFFREY · 2018 to 2022
$3.2M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancerR01CA253865 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI OZPOLAT, BULENT, WANG, ZHIHUI · 2021 to 2025
$2.0M
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA222007NCI NIH HHS R01 CA226537NCI NIH HHS R01 CA253865NIGMS NIH HHS R01 GM133198
6 · The paper itself

Abstract

Targeted bacteriophage (phage) particles are potentially attractive yet inexpensive platforms for immunization. Herein, we describe targeted phage capsid display of an immunogenically relevant epitope of the SARS-CoV-2 Spike protein that is empirically conserved, likely due to the high mutational cost among all variants identified to date. This observation may herald an approach to developing vaccine candidates for broad-spectrum, towards universal, protection against multiple emergent variants of coronavirus that cause COVID-19.

Identifiers

PMID34676381
PMCPMC8529634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.